Amgen hematology news

The U.S. Supreme Court agreed to hear a challenge from Amgen on a securities fraud suit alleging the biotech misled investors about the safety of anemia drugs Aranesp darbepoetin alfa and Epogen epoetin alfa. At issue is whether plaintiffs must prove that Amgen's alleged misrepresentations had a material effect on the stock price before a court can certify the group as a class. ...